The bipyridyl herbicide paraquat induces proteasome dysfunction in human neuroblastoma SH-SY5Y cells

被引:41
作者
Yang, Wonsuk
Tiffany-Castiglioni, Evelyn [1 ]
机构
[1] Texas A&M Univ, Dept Integrat Biosci, College Stn, TX 77843 USA
[2] Texas A&M Univ, Fac Toxicol, College Stn, TX 77843 USA
来源
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES | 2007年 / 70卷 / 21期
关键词
D O I
10.1080/15287390701459262
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Paraquat ( PQ) is suspected to be an environmental risk factor for Parkinson` s disease ( PD). A strong correlation between exposure to paraquat and the occurrence of PD was reported in Canada, Taiwan, and the United States. This correlation is supported by in vivo work showing that paraquat produces dopaminergic pathogenesis. In particular, paraquat forms abnormal protein aggregates in dopaminergic neurons of mice. However, it is not clear how paraquat produces this pathology. Given that proteasome dysfunction induces aberrant protein aggregation, it was hypothesized that paraquat induces proteasome dysfunction. To explore this possibility, proteasome activity and some factors possibly contributing to proteasome dysfunction were investigated in dopaminergic SY5Y cells treated with paraquat. Furthermore, levels of alpha- synuclein and ubiquitin- conjugated proteins were measured to test whether paraquat induces protein accumulation in SY5Y cells. Results showed that at a concentration of paraquat that reduced viability by about 60% at 48 h ( 0.5 mM) loss of proteasome activity occurred. In addition, the cells showed decreased ATP levels and reduced mitochondrial complex V activity. These changes were significant 24 h after treatment with paraquat. Furthermore, paraquat- treated cells showed decreased protein levels of proteasome 19S subunits, but not 20S alpha or beta subunits, suggesting that the effects observed were not the result of general cytotoxicity. Paraquat also increased levels of alpha- synuclein and ubiquitinated proteins, suggesting that paraquat- induced proteasome dysfunction leads to aberrant protein accumulation. Taken together, these findings support the hypothesis that paraquat impairs proteasome function in SY5Y cells.
引用
收藏
页码:1849 / 1857
页数:9
相关论文
共 76 条
[31]   Dopamine induces proteasome inhibition in neural PC12 cell line [J].
Keller, JN ;
Huang, FF ;
Dimayuga, ER ;
Maragos, WF .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 29 (10) :1037-1042
[32]   R-(-)-deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition [J].
Klegeris, A ;
McGeer, PL .
EXPERIMENTAL NEUROLOGY, 2000, 166 (02) :458-464
[33]   Mitochondria, Ca2+ and neurodegenerative disease [J].
Krieger, C ;
Duchen, MR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 447 (2-3) :177-188
[34]   Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-DOPA)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells - Effects of oxidative stress and antioxidative factors [J].
Lai, CT ;
Yu, PH .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (03) :363-372
[35]   CHRONIC PARKINSONISM IN HUMANS DUE TO A PRODUCT OF MEPERIDINE-ANALOG SYNTHESIS [J].
LANGSTON, JW ;
BALLARD, P ;
TETRUD, JW ;
IRWIN, I .
SCIENCE, 1983, 219 (4587) :979-980
[36]  
Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO
[37]  
2-F
[38]   MPP+ increases the vulnerability to oxidative stress rather than directly mediating oxidative damage in human neuroblastoma cells [J].
Lee, HS ;
Park, CW ;
Kim, YS .
EXPERIMENTAL NEUROLOGY, 2000, 165 (01) :164-171
[39]   Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: Relationships with 3,4-dihydroxyphenylacetaldehyde formation [J].
Legros, H ;
Dingeval, MG ;
Janin, F ;
Costentin, J ;
Bonnet, JJ .
NEUROTOXICOLOGY, 2004, 25 (03) :365-375
[40]   Effects of paraquat on the substantia nigra of the Wistar rats: Neurochemical, histological, and behavioral studies [J].
Liou, HH ;
Chen, RC ;
Tsai, YF ;
Chen, WP ;
Chang, YC ;
Tsai, MC .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1996, 137 (01) :34-41